[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339824-105":59,"doc-detail-339824-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","brain-biomarker-analysis-of-likely-tumor-origin-balto-octs-05-prospective-study","BRAIN BIOMARKER ANALYSIS OF LIKELY TUMOR ORIGIN (BALTO) - OCTS-05 - Prospective study","","Evaluating the sensitivity and specificity of a novel CSF-based DNA assay versus current standard-of-care for detecting CNS tumors. This multi-center prospective study enrolls about 400 patients with known or suspected CNS tumors, collecting CSF during routine care and sending 2–10 ml to Belay Diagnostics for testing with the Summit™ assay. De-identified results will be analyzed to determine assay performance for CNS tumor detection/diagnosis, using histopathology and CSF cytology as comparators while addressing limitations of low-sensitivity cytology.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/brain-biomarker-analysis-of-likely-tumor-origin-balto-octs-05-prospective-study/339824/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/brain-biomarker-analysis-of-likely-tumor-origin-balto-octs-05-prospective-study/339824.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the primary objective of the study?","Question",{"text":113,"@type":114},"To assess the sensitivity and specificity of the Summit™ assay compared with current standard of care for detecting CNS tumors from CSF.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is CSF obtained and tested in the study?",{"text":118,"@type":114},"CSF is collected as part of standard clinical care (2–10 ml) and sent to Belay Diagnostics for testing using the Summit™ assay.",{"name":120,"@type":111,"acceptedAnswer":121},"Which methods are used as comparators in evaluating the assay?",{"text":122,"@type":114},"The assay performance is evaluated against histopathology and CSF cytology, which are used as the current standard of care.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339824,1790535549,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":81,"preview_page_count":8,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Abstracts  \nnumber. The primary endpoint of this study is to assess the sensitivity and specificity of this novel assay as compared to the current standard of care. This is a multi-center study in patients with known or suspected CNS tumors, with a planned enrollment of 400 individuals. CSF will be collected as part of the standard clinical care in which 2-10 ml will be sent to Belay Diagnostics for testing using the Summit™ assay. Results will be returned to the investigator, and de-identified data will be evaluated to determine the sensitivity and specificity of the assay in the detection/diagnosis of CNS tumors from CSF.  \nABSTRACT CITATION ID: vdae090.090  \nOCTS-05  \nBRAIN BIOMARKER ANALYSIS OF LIKELY TUMOR ORIGIN  \n(BALTO)-A PROSPECTIVE STUDY FOR THE DETECTION/DIAG  \nNOSIS OF CNS TUMORS FROM CSF USING THE BELAY SUMMIT™  \nASSAY  \nMatthias Holdhoff1,2, Priya Kumthekar3, Honey Reddi4, Steph  \nanie Reiners4, Chetan Bettegowda1,2; 1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 2Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3The Feinberg School of Medicine at Northwestern University, Chicago, IL, USA. 4Belay Diagnostics, Chicago, IL, USA  \nCurrently, there is a lack of adequate sensitive and specific non-or minimally invasive molecular biomarker technologies to aid in the diagnosis of Central Nervous System (CNS) cancers in patients suspected of having disease based on clinical or radiological findings. Cerebrospinal fluid (CSF) cytology has low sensitivity, necessitating tissue sampling through invasive neurosurgical procedures in most cases. Tumor-derived DNA (ctDNA) has shown potential to detect brain and spinal cord neoplasms by evaluating CSF, offering promise in monitoring dynamic changes in disease burden and evolving mechanisms of resistance in patients undergoing treatment.  \nIn this study, we aim to bridge the gap in cytology by utilizing the Belay Summit™ assay, a next generation DNA sequencing-based platform, to identify and characterize tumor derived DNA in CSF across a diverse population in comparison to the current standard of care of histopathology and CSF cytology. Our objective is to demonstrate the performance of the Belay Summit™ assay to help clinicians diagnose and manage patients with suspected or known brain cancer by characterizing the ctDNA present in CSF based on methylation, mutation, and chromosomal copy  \ni24 NEURO-ONCOLOGY ADVANCES • AUGUST 2024","cbCaic4QpuPIA8sV","https://ap.wps.com/l/cbCaic4QpuPIA8sV","pdf",135074,"English","# Abstracts\n## Study endpoint and design\n## CSF collection and assay testing\n## Objectives and comparison to standard of care","[{\"question\":\"What is the primary objective of the study?\",\"answer\":\"To assess the sensitivity and specificity of the Summit™ assay compared with current standard of care for detecting CNS tumors from CSF.\"},{\"question\":\"How is CSF obtained and tested in the study?\",\"answer\":\"CSF is collected as part of standard clinical care (2–10 ml) and sent to Belay Diagnostics for testing using the Summit™ assay.\"},{\"question\":\"Which methods are used as comparators in evaluating the assay?\",\"answer\":\"The assay performance is evaluated against histopathology and CSF cytology, which are used as the current standard of care.\"}]","BRAIN BIOMARKER ANALYSIS OF LIKELY TUMOR ORIGIN (BALTO) - OCTS-05 - Prospective study | PDF",1790032457,[146],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97e9e08194362e6b1be153679f568018.webp",983,1296]